Company to buy
- Size: Small to medium business
- Sales: 3-30 million EUR
- Location: Europe
- Reason for acquisition: The management wants to expand and diversify their business
- #CFIE PHB156
Overview of the buyer for prescription medicine producers in Europe
The company is a global specialty pharmaceutical company focused on acquiring prescription medicines across a broad range of therapeutic areas in international markets. The company focuses its resources on acquiring and optimizing established medicines.
Profile (strategy) of the buyer for prescription medicine producers in Europe
The company has several prescription medicine products in the US, Canada, and Europe and has a strategy focused on acquiring prescription medicines in key international markets and in a broad range of therapeutic areas.
Contact us to get details about this buyer for prescription medicines producer Europe
Activities and products of a suitable target
The buyer is interested in prescription medicine manufacturers in Europe with a strong track record in the sector. In general, the management is open to considering good opportunities which may improve its growth and profitability and is also flexible to consider companies that do not strictly fit the above description.
Highlights for the buyer for prescription medicine producers in Europe
- The target company should have strong expertise in prescription medicines.
- The target company should operate in Europe
- Sales between 3-30 million EUR
More information on this buyer for prescription medicine producer in Europe
Please get in touch if you are interested in learning more about this buyer for prescription medicine producer in Europe. For more pharma manufacturer companies for sale please visit the section pharma manufacturer companies for sale. For other pharma manufacturer buyers, please visit the section pharma manufacturer companies wanted. If you are instead interested in pharma companies for sale, please visit the pharma companies for sale section. For pharma buyers, please visit the section pharma companies wanted.